SCHEMBL25124263

SCHEMBL25124263

C[C@@H]1CCCN(C2CCN(c3nnc(C(=O)O)s3)CC2)C1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 14/20 0.48
S1PR1 P21453 1/20 0.44
ADRA1A P35348 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25124424 0.85 HRH3 (0.44) HRH3S1PR1ADRA1A
SCHEMBL24183648 0.84 HRH3 (0.58) HRH3
SCHEMBL24183482 0.80 ADRA1A (0.41) HRH3ADRA1A
SCHEMBL24183427 0.79 ADRA1A (0.48) HRH3ADRA1A
SCHEMBL25124325 0.79 ADRA1A (0.48) HRH3ADRA1A
Hydrochloric Acid SCHEMBL29787308 0.78 ADRA1A (0.47) HRH3ADRA1A
Hydrochloric Acid SCHEMBL29787310 0.78 ADRA1A (0.47) HRH3ADRA1A
SCHEMBL12244652 0.76 HRH3 (0.71) HRH3
SCHEMBL30379965 0.74 ADRA2C (0.58) HRH3ADRA1A
SCHEMBL30359068 0.73 HRH3 (0.48) HRH3ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 US disclosed
CN-120136863-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-06-13 CN disclosed
CN-120025328-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 CN disclosed
CN-120025327-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-05-23 CN disclosed
CN-114929694-B Adrenergic receptor ADRAC2 antagonists 拜耳公司 2025-02-07 CN disclosed
CN-116057057-A Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea 拜耳公司 2023-05-02 CN disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
CN-114929694-A Adrenergic receptor ADRAC2 antagonists 拜耳公司 2022-08-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 HRH3 115/4885S1PR1 509/4885ADRA1A 14/4885
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 HRH3 55/4885S1PR1 767/4885ADRA1A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.